Skip to main content
OpenTrials
Completed

NCT Number: NCT01375712

Efficacy Evaluation of Probiotic Product on Bowel Habits in Healthy Subjects

The objective of this study is to evaluate if consumption of fermented milk containing Lactobacillus casei strain Shirota has an impact on stool consistency, stool frequency, constipation-related symptoms, and quality of life in subjects who frequently have hard or lumpy stools.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Harrison Clinical Research Deutschland GmbH

Munich, 80636, Germany

About this study

Constipation is a common problem affecting approximately 17% of the general population in Europe. Several reports suggest that production of hard or lumpy stools (HLS) is strongly associated with the development of constipation. HLS are produced not only by chronic constipated patient but also by healthy population. Thus, reducing the incidence of HLS might be beneficial in terms of reducing the incidence of constipation in healthy population.

The results of two clinical studies conducted in Europe indicate the positive effect of fermented milk (FM) containing Lactobacillus casei strain Shirota (LcS) to modulate the hardness or dryness of stools. Koebnick et al. (2003) reported that consumption of the FM drink containing LcS decreased the occurrence of hard or lumpy stools, and improved the severity of constipation in patients with chronic constipation in Germany. An open trial conducted in Ghent, Belgium used commercially available FM containing LcS (Yakult® Light) in subjects who frequently had hard or lumpy stools, screened by an average Bristol Stool Form Scale (BS) score < 3.0. After 3 weeks of treatment, the proportion of subjects who produced hard or lumpy stools (BS score = 1 or 2) ≥ 25% of bowel movements decreased from 73.7% at baseline to 36.8%, while in the non-intervention control group the proportion increased from 75.0% to 85.0% during the same period. Based on the results of those studies, it was anticipated that LcS might assist in reducing the production of hard or lumpy stools in the general population. In order to confirm the efficacy in healthy population, a randomised, double blind, placebo control study is required.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

; a subject:

  • is informed both verbally and in writing about the objectives of the clinical study, the methods, the anticipated benefits and potential risks and the discomfort to which he/she may be exposed, and give written consent to participate in the study prior to the start of any study-related procedures
  • is healthy female or male, 18-65 years of age, inclusive
  • is conscious of having hard or lumpy stools in daily life
  • has an average Bristol Stool Form Scale score <3.0 per bowel movement
  • female subjects of childbearing potential should use a reliable method of contraception

Exclusion criteria

; a subject:

  • is under the age of legal consent
  • is mentally or legally incapacitated
  • is treated by a doctor for her/his constipation
  • has a history of gastrointestinal surgery except for appendectomy
  • has a history of chronic gastrointestinal diseases, including but not limited to inflammatory bowel diseases
  • has a severe gastrointestinal disorder
  • has clinically relevant medical conditions, e.g., renal, hepatic, pulmonary, cardiac, hematological, endocrinological, neurological, or psychiatric conditions
  • is pregnant or wanting to become pregnant during the course of the study
  • is unable to refrain from or anticipates the use of any medication (including laxatives, diuretics, prescription and non-prescription drugs, vitamins and herbal supplements), except for paracetamol, oral contraceptives, or hormonal replacement therapy during the screening visit and for the duration of the study
  • has a history of drug and/or alcohol abuse
  • has milk allergies
  • is intolerant to lactose

Treatment and study plan

Fermented milk containing Lactobacillus casei strain Shirota

Dietary Supplement

A fermented milk containing Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10^9 colony-forming units of Lactobacillus casei strain Shirota.

Other names: Commercial name: Yakult

Placebo

Dietary Supplement

Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; and 0.9 g of protein.

Primary outcomes

  1. Change in the proportion of subjects who produce hard or lumpy stools not less than 25%(≥25%) of weekly number of bowel movements

    Time frame: During pre-treatment (2 weeks) and treatment (8 weeks)

    Hard or lumpy stools are defined as stools with Bristol Stool Form Scale score 1 or 2. Incidence of hard or lumpy stools is calculated by weekly basis.

Secondary outcomes

  1. Weekly average Bristol Stool Form Scale score

    Time frame: During pre-treatment (2 weeks) and treatment (8 weeks)

    Bristol Stool Form Scale is a medical aid designed to classify the form of stool with 7 levels; Separate hard lumps like nuts (difficult to pass), score=1; Sausage-shaped but lumpy, score=2;Like a sausage but with cracks on its surface, score=3; Like a sausage or snake, smooth and soft, score=4; Soft blobs with clear-cut edges (passed easily), score=5; Fluffy pieces with ragged edges, a mushy stool, score=6; Watery, no solid pieces, entirely liquid, score=7.

  2. Weekly number of spontaneous bowel movements

    Time frame: During pre-treatment (2 weeks) and treatment (8 weeks)

    Spontaneous bowel movement is defined as the bowel movements without laxative use

  3. Weekly number of spontaneous complete bowel movements

    Time frame: During pre-treatment (2 weeks) and treatment (8 weeks)

    Spontaneous complete bowel movement is defined as spontaneous bowel movement relieving the feeling of the presence of stool in the distal bowel.

  4. Patient Assessment of Constipation Symptoms (PAC-SYM) score

    Time frame: 6 points (Days 1, 15, 29, 43, 57 and 71)

    PAC-SYM contains 12 questions which are classified into 3 subdomains (stool symptoms, abdominal symptoms, and rectal symptoms). The average scores of total questionnaires and each subdomain are assessed.

  5. Patient Assessment of Constipation Quality of Life (PAC-QOL) score

    Time frame: 6 points (Days 1, 15, 29, 43, 57 and 71)

    PAC-QOL contains 28 questions which are classified into 4 subdomains (physical discomfort, worries and concerns, psychosocial discomfort, and satisfaction). The average scores of total questionnaires and each subdomain are assessed.

Sponsors and collaborators

Lead sponsor

Yakult Honsha Co., LTD

Industry

Registry information

Official study title

Evaluation of the Impact of a Fermented Milk Containing Lactobacillus Casei Strain Shirota on Stool Consistency, Stool Frequency, Constipation-related Symptoms and Quality of Life in People Who Frequently Have Hard or Lumpy Stools

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Jun 17, 2011
Registry last updated
Jan 31, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.